Format On-demand Duration 9 Hours - 2 Modules Total


$100 

Seminar Registration Options: *

Learn More


This masterclass builds the capability to classify, investigate, and document OOS and OOT events with disciplined scientific reasoning, reducing exposure to inspection findings, product impact decisions, and recurring quality failures while strengthening internal control over laboratory and manufacturing investigations.


Why Take This Course

Out-Of-Specification (OOS) And Out-Of-Trend (OOT) Results Signal Potential Breakdowns In Process Control, Product Quality, And Data Integrity. FDA Expectations Require Structured, Well-Documented Investigations That Distinguish Laboratory Error From True Manufacturing Or Analytical Issues. Inadequate Handling Of These Events Remains A Frequent Source Of Form 483 Observations, Warning Letters, Recalls, And Consent Decrees Across Pharmaceutical, Biotech, Dietary Supplement, And Contract Manufacturing Operations Operating Under CGMP Regulations.


This Course Presents A Detailed Progression From Initial Result Detection Through Classification, Investigation Phases, Root Cause Analysis, Interim Controls, CAPA Development, And Final Reporting. It Clarifies Phase I And Phase II Approaches, Trending Evaluation, Repeat Testing Considerations, And Documentation Standards Expected During Inspection. Real Enforcement Examples Are Used To Reinforce Disciplined Decision-Making And Strengthen Internal Investigation Practices.


Course Agenda


Module 1:


Foundations and Regulatory Framework

FDA definitions and guidance for OOS and OOT

Differences between OOS, OOT, and OOE (Out of Expectation)

Phase I vs Phase II Investigations

Laboratory investigation steps and best practices

Assigning preliminary causes and assessing lab error

Deviation and non-conformance documentation

Real-world OOS case studies

Data integrity risks in OOS handling


Module 2:


Root Cause, CAPA, and Regulatory Expectations

Conducting effective root cause analysis

CAPA development and effectiveness checks

Linkage to batch disposition decisions

Statistical evaluation and OOT trending

Handling repeat results and retesting/averaging

Documentation standards for FDA inspection readiness

Responding to 483s and regulatory expectations for OOS/OOT



Why Strong OOS/OOT Investigations Matter

Effective Handling Of Atypical Results Directly Influences Batch Disposition, Regulatory Exposure, And Overall Quality Credibility. This Course Strengthens Decision-Making Around Investigation Triggers, Retesting Practices, Trending Evaluation, And CAPA Linkage, Helping Organizations Avoid Procedural Gaps That Frequently Surface During FDA Inspections Under CGMP Oversight.


How This Course Structure Builds Investigation Discipline

The Seminar Follows The Natural Progression Of An Atypical Result, Beginning With Regulatory Definitions And Laboratory Assessment Before Advancing To Root Cause Evaluation, Corrective Actions, And Inspection Readiness. Each Stage Builds On The Prior Discussion, Reinforcing Cumulative Reasoning Rather Than Isolated Topics, And Mirroring How Investigations Unfold In Real Operations.


Who Should Attend

Quality Assurance Departments

Quality Control Departments

Manufacturing Departments

Operations Departments

Regulatory Affairs Departments

Compliance Departments

Validation Departments

Technical Services

Auditing/Internal Auditors

Laboratory Analysts

CAPA Coordinators

Site Heads and Directors of Quality



Course Director: Meredith L. Crabtree


Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.